Clarametyx Biosciences has initiated a Phase 2a trial for CMTX-101, an antibody therapy targeting bacterial biofilms in cystic fibrosis patients with chronic pulmonary infections.
Clarametyx Biosciences has initiated the Phase 2a portion of its clinical trial evaluating CMTX-101 for cystic fibrosis (CF)-associated pulmonary infections.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.